Immune‐mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non‐small cell lung cancer patient: A case report

We describe a case of a 60‐year‐old man with a prolonged thrombocytopenia during a durvalumab maintenance therapy after chemoradiotherapy for locally advanced non‐small cell lung carcinoma. Bone marrow specimen was normoplastic with the marked megakaryocyte depletion, which was assumed to be an acqu...

Descripción completa

Detalles Bibliográficos
Autores principales: Makiguchi, Tomonori, Tanaka, Hisashi, Kamata, Kosuke, Taima, Kageaki, Kurose, Akira, Tasaka, Sadatomo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520809/
https://www.ncbi.nlm.nih.gov/pubmed/34405563
http://dx.doi.org/10.1111/1759-7714.14106
_version_ 1784584749426147328
author Makiguchi, Tomonori
Tanaka, Hisashi
Kamata, Kosuke
Taima, Kageaki
Kurose, Akira
Tasaka, Sadatomo
author_facet Makiguchi, Tomonori
Tanaka, Hisashi
Kamata, Kosuke
Taima, Kageaki
Kurose, Akira
Tasaka, Sadatomo
author_sort Makiguchi, Tomonori
collection PubMed
description We describe a case of a 60‐year‐old man with a prolonged thrombocytopenia during a durvalumab maintenance therapy after chemoradiotherapy for locally advanced non‐small cell lung carcinoma. Bone marrow specimen was normoplastic with the marked megakaryocyte depletion, which was assumed to be an acquired amegakaryocytic thrombocytopenic purpura. Although hematological disorders as immune‐related adverse events (irAE) are rare, we should pay more attention to hematological disorders with durvalumab especially after concurrent chemoradiotherapy.
format Online
Article
Text
id pubmed-8520809
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-85208092021-10-25 Immune‐mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non‐small cell lung cancer patient: A case report Makiguchi, Tomonori Tanaka, Hisashi Kamata, Kosuke Taima, Kageaki Kurose, Akira Tasaka, Sadatomo Thorac Cancer Case Reports We describe a case of a 60‐year‐old man with a prolonged thrombocytopenia during a durvalumab maintenance therapy after chemoradiotherapy for locally advanced non‐small cell lung carcinoma. Bone marrow specimen was normoplastic with the marked megakaryocyte depletion, which was assumed to be an acquired amegakaryocytic thrombocytopenic purpura. Although hematological disorders as immune‐related adverse events (irAE) are rare, we should pay more attention to hematological disorders with durvalumab especially after concurrent chemoradiotherapy. John Wiley & Sons Australia, Ltd 2021-08-17 2021-10 /pmc/articles/PMC8520809/ /pubmed/34405563 http://dx.doi.org/10.1111/1759-7714.14106 Text en © 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Makiguchi, Tomonori
Tanaka, Hisashi
Kamata, Kosuke
Taima, Kageaki
Kurose, Akira
Tasaka, Sadatomo
Immune‐mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non‐small cell lung cancer patient: A case report
title Immune‐mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non‐small cell lung cancer patient: A case report
title_full Immune‐mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non‐small cell lung cancer patient: A case report
title_fullStr Immune‐mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non‐small cell lung cancer patient: A case report
title_full_unstemmed Immune‐mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non‐small cell lung cancer patient: A case report
title_short Immune‐mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non‐small cell lung cancer patient: A case report
title_sort immune‐mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non‐small cell lung cancer patient: a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520809/
https://www.ncbi.nlm.nih.gov/pubmed/34405563
http://dx.doi.org/10.1111/1759-7714.14106
work_keys_str_mv AT makiguchitomonori immunemediatedthrombocytopeniainducedwithdurvalumabafterchemoradiotherapyinanonsmallcelllungcancerpatientacasereport
AT tanakahisashi immunemediatedthrombocytopeniainducedwithdurvalumabafterchemoradiotherapyinanonsmallcelllungcancerpatientacasereport
AT kamatakosuke immunemediatedthrombocytopeniainducedwithdurvalumabafterchemoradiotherapyinanonsmallcelllungcancerpatientacasereport
AT taimakageaki immunemediatedthrombocytopeniainducedwithdurvalumabafterchemoradiotherapyinanonsmallcelllungcancerpatientacasereport
AT kuroseakira immunemediatedthrombocytopeniainducedwithdurvalumabafterchemoradiotherapyinanonsmallcelllungcancerpatientacasereport
AT tasakasadatomo immunemediatedthrombocytopeniainducedwithdurvalumabafterchemoradiotherapyinanonsmallcelllungcancerpatientacasereport

Ejemplares similares